Literature DB >> 20139025

Long-term follow-up of an intensified myeloablative conditioning regimen with in vivo T cell depletion followed by allografting in patients with advanced multiple myeloma.

Nicolaus Kröger1, Hermann Einsele, Günter Derigs, Hannes Wandt, Andreas Krüll, Axel Zander.   

Abstract

We report long-term results after a median follow-up of 105 months in 18 patients with multiple myeloma who received an intensified myeloablative conditioning regimen regimen consisting of modified total body irradiation, busulfan, cyclophosphamide, and antithymocyte globulin, followed by allogeneic stem cell transplantation (SCT). Grade II-IV acute graft-versus-host disease occurred in 7 patients (44%), and treatment-related mortality was 17%. Complete remission (CR) with negative immunofixation after allogeneic SCT occurred in 53% of the patients. For all patients, the estimated overall survival at 12 years was 50% (95% confidence interval [CI], 26%-74%), and the estimated event-free survival (EFS) was 35% (95% CI, 23%-57%). Those patients who achieved CR after SCT had a 12-year estimated PFS of 60%, whereas none of the patients without CR remained progression-free. Our data indicate that an intensified myeloablative conditioning regimen followed by allogeneic SCT can produce long-term survival and freedom from disease in patients with multiple myeloma who achieve CR. Copyright 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20139025     DOI: 10.1016/j.bbmt.2010.01.018

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  3 in total

1.  Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution.

Authors:  L Rosiñol; R Jiménez; M Rovira; C Martínez; F Fernández-Avilés; P Marín; M Suárez-Lledó; G Gutiérrez-García; C Fernández de Larrea; E Carreras; A Urbano-Ispizua; J Bladé
Journal:  Bone Marrow Transplant       Date:  2015-01-26       Impact factor: 5.483

Review 2.  Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma.

Authors:  Jean-Sébastien Claveau; Francis K Buadi; Shaji Kumar
Journal:  Oncol Ther       Date:  2022-04-04

3.  Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017.

Authors:  Xuejiao Yin; Liang Tang; Fengjuan Fan; Qinyue Jiang; Chunyan Sun; Yu Hu
Journal:  Cancer Cell Int       Date:  2018-04-23       Impact factor: 5.722

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.